Catalyst Dossier · compiled by CeliA 🧫

CEL SCI CORP (CVM)

Biological Products, (No Diagnostic Substances) · market cap $9M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Cel-Sci Corporation (CVM) is a micro-cap clinical-stage immunotherapy company with a single disclosed pipeline asset, LEAPS Immunomodulatory (LI), currently in Phase 3 for squamous cell carcinoma of the oral cavity. At a market cap of ~$11M and reported cash of only $1.9M (~0.7 months of runway), the company faces an acute liquidity crisis that existentially overshadows any clinical optionality. No revenue has been reported in any of the last five fiscal years.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
LI	Phase 3	Squamous Cell Carcinoma of the Oral Cavity

Price & technical context

3-month

+24.4%

6-month

-70.5%

12-month

-78.9%

52-wk range

$0.97–$13.04

vs 50-day MA

+19.4%

vs 200-day MA

-61.2%

Realized vol

115.7%

Max drawdown

-97.7%

Daily closes through 2026-08-12. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for CVM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.